Question 1

What is ResMed's P/B ratio?

Accepted Answer

ResMed (RMD) P/B ratio is 4.4× as of June 5, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for ResMed?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For ResMed specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is ResMed's P/B ratio high or low?

Accepted Answer

ResMed's P/B ratio of 4.4× is below its own 5-year average of 7.8× and above the sector median of 3.4×. That places the current reading at the 0th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is ResMed's historical P/B ratio range?

Accepted Answer

In the available daily series, ResMed (RMD) P/B ratio has ranged from a low of 2.4× in 2011 to a high of 15.1× in 2021. The 5-year average is 7.8× and the 5-year median is 6.7×.

Question 7

What was ResMed's P/B ratio in 2025?

Accepted Answer

ResMed (RMD) P/B ratio at the end of 2025 was 6.3×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does ResMed's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$37.79B	$5.97B	6.3×	+0.7×	Jun 30, 2025
2024	$27.46B	$4.86B	5.6×	-2.1×	Jun 30, 2024
2023	$32.12B	$4.13B	7.8×	-1.4×	Jun 30, 2023
2022	$30.68B	$3.36B	9.1×	-3.3×	Jun 30, 2022
2021	$35.89B	$2.89B	12.4×	+1.3×	Jun 30, 2021
2020	$27.80B	$2.50B	11.1×	+2.6×	Jun 30, 2020
2019	$17.75B	$2.07B	8.6×	+1.4×	Jun 30, 2019
2018	$14.79B	$2.06B	7.2×	+1.5×	Jun 30, 2018
2017	$11.06B	$1.96B	5.6×	+0.4×	Jun 30, 2017
2016	$8.89B	$1.69B	5.2×	+0.2×	Jun 30, 2016
2015	$7.94B	$1.59B	5.0×	+1.0×	Jun 30, 2015
2014	$7.12B	$1.76B	4.0×	+0.1×	Jun 30, 2014
2013	$6.38B	$1.61B	4.0×	+1.2×	Jun 30, 2013
2012	$4.45B	$1.61B	2.8×	+0.0×	Jun 30, 2012
2011	$4.72B	$1.73B	2.7×	-0.8×	Jun 30, 2011
2010	$4.61B	$1.29B	3.6×	+0.8×	Jun 30, 2010
2009	$3.07B	$1.12B	2.8×	+0.3×	Jun 30, 2009
2008	$2.70B	$1.08B	2.5×	-0.9×	Jun 30, 2008
2007	$3.20B	$931.22M	3.4×	-1.4×	Jun 30, 2007
2006	$3.55B	$738.15M	4.8×	-0.1×	Jun 30, 2006
2005	$2.30B	$474.06M	4.9×	+0.1×	Jun 30, 2005
2004	$1.72B	$361.50M	4.8×	+0.2×	Jun 30, 2004
2003	$1.30B	$286.43M	4.6×	-0.2×	Jun 30, 2003
2002	$910.92M	$192.93M	4.7×	—	Jun 30, 2002


Quest Diagnostics (DGX)	2.9×
Moderna (MRNA)	2.7×
Charles River (CRL)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Danaher (DHR)	2.4×
UnitedHealth Group (UNH)	2.4×
Solventum (SOLV)	2.3×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Molina Healthcare (MOH)	1.7×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Elevance Health (ELV)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Revvity (RVTY)	1.4×
Zimmer Biomet Holdings (ZBH)	1.2×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Centene (CNC)	0.8×

P/B Ratio for ResMed (RMD)

P/B Ratio daily chart for ResMed (RMD)

Historical P/B Ratio for ResMed (RMD) from 2002 to 2025

About P/B Ratio at ResMed (RMD)

ResMed P/B Ratio by Year

ResMed P/B Ratio 2025: 6.3×

ResMed P/B Ratio 2024: 5.6×

ResMed P/B Ratio 2023: 7.8×

ResMed P/B Ratio 2022: 9.1×

ResMed P/B Ratio 2021: 12.4×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

ResMed (RMD) Key Financials

P/B Ratio daily chart for ResMed (RMD)

Historical P/B Ratio for ResMed (RMD) from 2002 to 2025

About P/B Ratio at ResMed (RMD)

ResMed P/B Ratio by Year

ResMed P/B Ratio 2025: 6.3×

ResMed P/B Ratio 2024: 5.6×

ResMed P/B Ratio 2023: 7.8×

ResMed P/B Ratio 2022: 9.1×

ResMed P/B Ratio 2021: 12.4×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

+What is ResMed's P/B ratio?

+How is the P/B ratio calculated?

+What is the P/B ratio?

+What is a good P/B ratio for ResMed?

+Is ResMed's P/B ratio high or low?

+What is ResMed's historical P/B ratio range?

+What was ResMed's P/B ratio in 2025?

+Why does ResMed's P/B ratio change over time?

ResMed (RMD) Key Financials